Company Description

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States.

It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells.

Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor.

The company was incorporated in 2019 and is based in Millbrae, California.